George Bickerstaff Elected to Inovio’s Board of Directors
March 21 2017 - 8:00AM
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today the
election of George Bickerstaff to its Board of Directors.
Mr. Bickerstaff is an internationally recognized
expert in finance, healthcare and information technology. He
has served Novartis Pharma AG as its chief financial officer and
held senior financial positions at IMS Health, Dun & Bradstreet
and General Electric. He serves on numerous boards and is currently
partner and managing director of M.M. Dillon & Co., an
investment bank and financial advisory firm.
Dr. J. Joseph Kim, Inovio's President and CEO,
said, "George Bickerstaff’s finance, operations and international
business experience will be an asset to Inovio as we advance our
products to commercialization and enter collaborative arrangements
with other companies. The addition of George to our Board helps
ensure that Inovio will continue to benefit from a deep and wide
range of experience.”
About Inovio Pharmaceuticals,
Inc.
Inovio is taking immunotherapy to the next level in
the fight against cancer and infectious diseases. We are the only
immunotherapy company that has reported generating T cells in vivo
in high quantity that are fully functional and whose killing
capacity correlates with relevant clinical outcomes with a
favorable safety profile. With an expanding portfolio of immune
therapies, the company is advancing a growing preclinical and
clinical stage product pipeline. Partners and collaborators include
MedImmune, The Wistar Institute, University of Pennsylvania, DARPA,
GeneOne Life Science, Plumbline Life Sciences, ApolloBio
Corporation, Drexel University, NIH, HIV Vaccines Trial Network,
National Cancer Institute, U.S. Military HIV Research Program, and
Laval University. For more information, visit www.inovio.com.
This press release contains certain forward-looking
statements relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines, our expectations regarding our research and development
programs and our capital resources. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, clinical trials and product development programs, the
availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation
technology as a delivery mechanism or develop viable DNA vaccines,
our ability to support our broad pipeline of SynCon® active
immunotherapy and vaccine products, the ability of our
collaborators to attain development and commercial milestones for
products we license and product sales that will enable us to
receive future payments and royalties, the adequacy of our capital
resources, the availability or potential availability of
alternative therapies or treatments for the conditions targeted by
the company or its collaborators, including alternatives that may
be more efficacious or cost effective than any therapy or treatment
that the company and its collaborators hope to develop, issues
involving product liability, issues involving patents and whether
they or licenses to them will provide the company with meaningful
protection from others using the covered technologies, whether such
proprietary rights are enforceable or defensible or infringe or
allegedly infringe on rights of others or can withstand claims of
invalidity and whether the company can finance or devote other
significant resources that may be necessary to prosecute, protect
or defend them, the level of corporate expenditures, assessments of
the company's technology by potential corporate or other partners
or collaborators, capital market conditions, the impact of
government healthcare proposals and other factors set forth in our
Annual Report on Form 10-K for the year ended December 31, 2016,
and other regulatory filings from time to time. There can be no
assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Aug 2023 to Aug 2024